source
- Company issues corporate announcement on senior employee transactionThe company released a corporate announcement identified as item 18/2026. The notice indicates that a transaction involving a leading employee has taken place. No further details about the nature…
- Replimune’s Tudriqev immunotherapy receives FDA accelerated approval for advanced melanomaReplimune announced that the FDA granted accelerated approval for its immunotherapy, now branded Tudriqev, in combination with Bristol Myers Squibb’s Opdivo. The decision follows two earlier reject…